Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2005-08-23
2005-08-23
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S194100, C424S184100, C424S400000, C530S403000, C530S404000, C530S405000, C530S406000, C435S235100
Reexamination Certificate
active
06932971
ABSTRACT:
The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.
REFERENCES:
patent: 3819706 (1974-06-01), Mehta
patent: 3885046 (1975-05-01), Mehta
patent: 3888866 (1975-06-01), Leute et al.
patent: 4123431 (1978-10-01), Soffer et al.
patent: 4197237 (1980-04-01), Leute et al.
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4788189 (1988-11-01), Glazer
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5071651 (1991-12-01), Sabara et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5256409 (1993-10-01), Blincko
patent: 5334394 (1994-08-01), Kossovsky et al.
patent: 5374426 (1994-12-01), Sabara et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 5876727 (1999-03-01), Swain et al.
patent: 5928647 (1999-07-01), Rock
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6232082 (2001-05-01), Ennifar et al.
patent: 6380364 (2002-04-01), Mueller et al.
patent: 6699474 (2004-03-01), Cerny
patent: 6719978 (2004-04-01), Schiller et al.
patent: 2002/0064529 (2002-05-01), Bohannon
patent: 2002/0064533 (2002-05-01), Murray
patent: 2002/0081295 (2002-06-01), Schiller et al.
patent: 2003/0157479 (2003-08-01), Bachmann et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2003/0175711 (2003-09-01), Renner et al.
patent: 2004/0076611 (2004-04-01), Bachmann et al.
patent: 2004/0136962 (2004-07-01), Renner et al.
patent: 0 259 149 (1993-12-01), None
patent: 0 576 357 (1993-12-01), None
patent: 0 385 610 (1994-03-01), None
patent: 0 465 081 (1994-04-01), None
patent: 0 283 505 (1994-07-01), None
patent: 0 425 082 (1995-04-01), None
patent: 0 656 354 (1995-06-01), None
patent: 2695563 (1994-03-01), None
patent: WO 92/03163 (1992-03-01), None
patent: WO 92/11291 (1992-07-01), None
patent: WO 92/13081 (1992-08-01), None
patent: WO 92/21333 (1992-12-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 94/15585 (1994-07-01), None
patent: WO 94/28888 (1994-12-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 96/05293 (1996-02-01), None
patent: WO 96/30049 (1996-10-01), None
patent: WO 96/30523 (1996-10-01), None
patent: WO 96/30049 (1997-03-01), None
patent: WO 97/31948 (1997-09-01), None
patent: WO 98/14216 (1998-04-01), None
patent: WO 98/15631 (1998-04-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/17803 (1999-04-01), None
patent: WO 99/28478 (1999-06-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/61054 (1999-12-01), None
patent: WO 99/67293 (1999-12-01), None
patent: WO 00/00462 (2000-01-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/50461 (2000-08-01), None
patent: WO 00/59928 (2000-10-01), None
patent: WO 01/12176 (2001-02-01), None
patent: WO 01/12176 (2001-02-01), None
patent: WO 01/62284 (2001-08-01), None
patent: WO 01/77158 (2001-10-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 01/98333 (2001-12-01), None
patent: WO 01/98333 (2001-12-01), None
patent: WO 02/14478 (2002-02-01), None
patent: WO 02/056905 (2002-07-01), None
patent: WO 02/058635 (2002-08-01), None
patent: WO 02/058635 (2002-08-01), None
patent: WO 03/040105 (2003-05-01), None
Fehr et al. PNAS 95: 9477-9481, 1998.
Abad, A., et al., “Comparison of a Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay and Gas Chromatography for the Determination of Nicotine in Cigarette Smoke Condensates,”Anal Chem. 65:3227-3231, American Chemical Society (1993).
Bonese, K.F., et al., “Changes in heroin self-administration by a rhesus monkey after morphine immunisation,”Nature252:708-710, Nature Publishing Group (1974).
Byrnes-Blake, K.A., et al., “Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats,”Int. Immunopharmacol.1:329-338, Elsevier (Feb. 2001).
Carpino, L.A., “1-Hydroxy-7-azabenzotriazole. An Efficient Peptide Coupling Additive,”J. Am. Chem. Soc.115:4397-4398, American Chemical Society (1993).
Carrera, M.R., et al., “Suppression of psychoactive effects of cocaine by active immunization,”Nature378:727-730, Nature Publishing Group (1995).
Carrera, M.R., et al., “Cocaine vaccines: Antibody protection against relapse in a rat model,”Proc. NatI. Acad. Sci. USA97:6202-6206, National Academy Press (2000).
Carrera, M.R., et al., “A second-generation vaccine protects against the psychoactive effects of cocaine,”Proc. Natl. Acad. Sci. USA98:1988-1992, National Academy Press (Feb. 2001).
Castaldi, G., et aI., “Tartaric Acid, an Efficient Chiral Auxiliary: New Asymmetric Synthesis of 2-Alkyl-2-arylacetic Acids,”J. Org. Chem.52:3018-3027, American Chemical Society (1987).
Castro, A., and Prieto, I., “Nicotine antibody production: comparison of two nicotine conjugates in different animal species,”Biochem. Biophys. Res. Commun.67:583-589, Academic Press (1975).
Castro, A., et al, “Nicotine Antibodies: Comparison of Ligand Specificities of Antibodies Produced against Two Nicotine Conjugates,”Eur. J. Biochem.104:331-340, Blackwell Publishing (1990).
Cohen, C., et al., “SR141716, a central cannabinoid (CB2) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats,”Behav. Pharmacol.13:451-463, Lippincott Williams & Wilkins (2002).
da Costa, C.L., et al., “Stopping Smoking: A prospective, Randomized, Double-Blind Study Comparing Nortriptyline to Placebo,”Chest122:403-408, The American College of Chest Physicians (Aug. 2002).
Fox, B.S., et aI., “Efficacy of a therapeutic cocaine vaccine in rodent models,” Nat. Med. 2:1129-1132, Nature Publishing Group (1996).
Hardin, J.S., et al., “Pharmacodynamics of a Monoclonal Antiphencyclidine Fab with Broad Selectivity for Phencyclidine-Like Drugs,”J. Pharmacol. Exp. Ther.285:1113-1122, The American Society for Pharmacology and Experimental Therapeutics (1998).
Hieda, Y., et al., “Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain,”Int. J. Immunopharmacol.22:809-819, Elsevier Science Ltd. (2000).
Hieda, Y., et al., “Active Immunization Alters the Plasma Nicotine Concentration in Rats,”J. Pharmacol. Exp. Ther.283:1076-1081, The American Society for Pharmacology and Experimental Therapeutics (1997).
Hieda, Y., et al., “Immunization of rats reduces nicotine distribution to brain,”Psychopharmacology(Berl) 143:150-157, Springer-Verlag (1999).
Hodge, L.M., et al., “Immuno
Bachmann Martin F.
Maurer Patrik
Cytos Biotechnology AG
Mosher Mary E.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Hapten-carrier conjugates and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hapten-carrier conjugates and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hapten-carrier conjugates and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3468657